| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 75.71 | 12.2% |
| Total Income | 75.71 | 12.2% |
| Expenditure | 86.37 | 7.2% |
| PBT | -10.84 | 14.4% |
| Net Profit | -10.90 | 14.8% |
| OPM | -14.07% | 5.33pp |
| NPM | -14.40% | 4.56pp |
| EPS | -0.26 | 16.1% |
AngioDynamics Reports Q1 FY2026: Med Tech Growth of 26.1%
04 May 2026 · 4 May, 9:04 am
Summary
AngioDynamics reported a strong first quarter for fiscal year 2026, with net sales increasing by 12.2% to $75.7 million. Med Tech net sales saw significant growth of 26.1%, driven by solid performance across the Auryon, thrombus management, and NanoKnife platforms. The company's adjusted EBITDA improved to $2.2 million, compared to $(0.2) million in the prior year. AngioDynamics raised its full year FY 2026 guidance for net sales, Med Tech net sales growth, Adjusted EBITDA and Adjusted EPS, reflecting confidence in continued momentum.
Key Highlights
- 1
AngioDynamics reported net sales of $75.7 million for the first quarter of fiscal year 2026, representing a 12.2% increase compared to the prior-year quarter.
- 2
Med Tech net sales increased by 26.1% to $35.3 million, driven by the Auryon, thrombus management, and NanoKnife platforms.
- 3
The company's Med Device net sales were $40.4 million, a 2.3% increase compared to the prior-year period.
- 4
Adjusted EBITDA for the first quarter of fiscal 2026 was $2.2 million, compared to $(0.2) million in the first quarter of fiscal 2025.
- 5
GAAP gross margin for the first quarter of fiscal 2026 was 55.3%, an increase of 90 basis points compared to the first quarter of fiscal 2025.
- 6
The company raised its full year FY 2026 guidance for net sales to $308 - $313 million and Med Tech net sales growth to 14% - 16%.
- 7
AngioDynamics ended the first quarter of fiscal 2026 with $38.8 million in cash and cash equivalents.
Management Comments
Jim Clemmer
"We had an outstanding first quarter as we continued to build off of the strong momentum created in fiscal 2025. Our strategy to bring unique platform technologies to large, fast growing global markets has paid off as we reported our fourth quarter in a row of MedTech growth of over 20%. This continued performance, combined with our disciplined focus on operational excellence, is driving sustained profitable growth.” “Our exceptional team is executing our vision to deliver transformative technologies that expand treatment options and help patients live healthier, happier lives. With our superior technologies supported by our clinical investments and the strength of our balance sheet, we remain well-positioned to drive consistent, profitable growth, and deliver sustained value creation during the balance of 2026 and beyond.”
Informational and educational content only. Not investment advice.